Pharmacoepigenomic Interventions As Novel Potential Treatments for Alzheimer's and Parkinson's Diseases

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2018 Oct 19

PMID 30332838

Citations 23

Authors

Oscar Teijido

Ramon Cacabelos

Affiliations

Soon will be listed here.

Abstract

Cerebrovascular and neurodegenerative disorders affect one billion people around the world and result from a combination of genomic, epigenomic, metabolic, and environmental factors. Diagnosis at late stages of disease progression, limited knowledge of gene biomarkers and molecular mechanisms of the pathology, and conventional compounds based on symptomatic rather than mechanistic features, determine the lack of success of current treatments, including current FDA-approved conventional drugs. The epigenetic approach opens new avenues for the detection of early presymptomatic pathological events that would allow the implementation of novel strategies in order to stop or delay the pathological process. The reversibility and potential restoring of epigenetic aberrations along with their potential use as targets for pharmacological and dietary interventions sited the use of epidrugs as potential novel candidates for successful treatments of multifactorial disorders involving neurodegeneration. This manuscript includes a description of the most relevant epigenetic mechanisms involved in the most prevalent neurodegenerative disorders worldwide, as well as the main potential epigenetic-based compounds under investigation for treatment of those disorders and their limitations.

Citing Articles

Targeting natural antioxidant polyphenols to protect neuroinflammation and neurodegenerative diseases: a comprehensive review.

Jalouli M, Rahman M, Biswas P, Rahman H, Harrath A, Lee I Front Pharmacol. 2025; 16:1492517.

PMID: 39981183 PMC: 11840759. DOI: 10.3389/fphar.2025.1492517.

Epigenetic Explorations of Neurological Disorders, the Identification Methods, and Therapeutic Avenues.

Firdaus Z, Li X Int J Mol Sci. 2024; 25(21).

PMID: 39519209 PMC: 11546397. DOI: 10.3390/ijms252111658.

The epigenetic modification of DNA methylation in neurological diseases.

Li L, Chen R, Zhang H, Li J, Huang H, Weng J Front Immunol. 2024; 15:1401962.

PMID: 39376563 PMC: 11456496. DOI: 10.3389/fimmu.2024.1401962.

Histone post-translational modification and heterochromatin alterations in neurodegeneration: revealing novel disease pathways and potential therapeutics.

Fisher R, Torrente M Front Mol Neurosci. 2024; 17:1456052.

PMID: 39346681 PMC: 11427407. DOI: 10.3389/fnmol.2024.1456052.

Unraveling the Epigenetic Landscape: Insights into Parkinson's Disease, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis.

Di Martino P, Marcozzi V, Bibbo S, Ghinassi B, Di Baldassarre A, Gaggi G Brain Sci. 2024; 14(6).

PMID: 38928553 PMC: 11202179. DOI: 10.3390/brainsci14060553.

References

Devi L, Raghavendran V, Prabhu B, Avadhani N, Anandatheerthavarada H . Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem. 2008; 283(14):9089-100. PMC: 2431021. DOI: 10.1074/jbc.M710012200. View

Arrowsmith C, Bountra C, Fish P, Lee K, Schapira M . Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov. 2012; 11(5):384-400. DOI: 10.1038/nrd3674. View

Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai L . Recovery of learning and memory is associated with chromatin remodelling. Nature. 2007; 447(7141):178-82. DOI: 10.1038/nature05772. View

Sussmuth S, Haider S, Landwehrmeyer G, Farmer R, Frost C, Tripepi G . An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease. Br J Clin Pharmacol. 2014; 79(3):465-76. PMC: 4345957. DOI: 10.1111/bcp.12512. View

Duan W, Ladenheim B, Cutler R, Kruman I, Cadet J, Mattson M . Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem. 2002; 80(1):101-10. DOI: 10.1046/j.0022-3042.2001.00676.x. View

Kouzarides T . Chromatin modifications and their function. Cell. 2007; 128(4):693-705. DOI: 10.1016/j.cell.2007.02.005. View

Marinova Z, Ren M, Wendland J, Leng Y, Liang M, Yasuda S . Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. J Neurochem. 2009; 111(4):976-87. PMC: 2766424. DOI: 10.1111/j.1471-4159.2009.06385.x. View

Kanfi Y, Naiman S, Amir G, Peshti V, Zinman G, Nahum L . The sirtuin SIRT6 regulates lifespan in male mice. Nature. 2012; 483(7388):218-21. DOI: 10.1038/nature10815. View

Kubota T, Takae H, Miyake K . Epigenetic mechanisms and therapeutic perspectives for neurodevelopmental disorders. Pharmaceuticals (Basel). 2013; 5(4):369-83. PMC: 3763642. DOI: 10.3390/ph5040369. View

10.

Nebbioso A, Carafa V, Benedetti R, Altucci L . Trials with 'epigenetic' drugs: an update. Mol Oncol. 2012; 6(6):657-82. PMC: 5528349. DOI: 10.1016/j.molonc.2012.09.004. View

11.

Monti B, Gatta V, Piretti F, Raffaelli S, Virgili M, Contestabile A . Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein. Neurotox Res. 2009; 17(2):130-41. DOI: 10.1007/s12640-009-9090-5. View

12.

Nicholas A, Lubin F, Hallett P, Vattem P, Ravenscroft P, Bezard E . Striatal histone modifications in models of levodopa-induced dyskinesia. J Neurochem. 2008; 106(1):486-94. DOI: 10.1111/j.1471-4159.2008.05417.x. View

13.

Zhang K, Schrag M, Crofton A, Trivedi R, Vinters H, Kirsch W . Targeted proteomics for quantification of histone acetylation in Alzheimer's disease. Proteomics. 2012; 12(8):1261-8. PMC: 6812507. DOI: 10.1002/pmic.201200010. View

14.

Masliah E, Dumaop W, Galasko D, Desplats P . Distinctive patterns of DNA methylation associated with Parkinson disease: identification of concordant epigenetic changes in brain and peripheral blood leukocytes. Epigenetics. 2013; 8(10):1030-8. PMC: 3891683. DOI: 10.4161/epi.25865. View

15.

Lee M, Wynder C, Schmidt D, McCafferty D, Shiekhattar R . Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem Biol. 2006; 13(6):563-7. DOI: 10.1016/j.chembiol.2006.05.004. View

16.

Yu C, Chang P, Hsin L, Chern J . Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease. J Med Chem. 2013; 56(17):6775-91. DOI: 10.1021/jm400564j. View

17.

Lewandowski N, Ju S, Verbitsky M, Ross B, Geddie M, Rockenstein E . Polyamine pathway contributes to the pathogenesis of Parkinson disease. Proc Natl Acad Sci U S A. 2010; 107(39):16970-5. PMC: 2947879. DOI: 10.1073/pnas.1011751107. View

18.

Zhu H, Wang L, Wang M, Song B, Tan S, Teng J . MicroRNA-195 downregulates Alzheimer's disease amyloid-β production by targeting BACE1. Brain Res Bull. 2012; 88(6):596-601. DOI: 10.1016/j.brainresbull.2012.05.018. View

19.

Rumpf T, Schiedel M, Karaman B, Roessler C, North B, Lehotzky A . Selective Sirt2 inhibition by ligand-induced rearrangement of the active site. Nat Commun. 2015; 6:6263. PMC: 4339887. DOI: 10.1038/ncomms7263. View

20.

Baum L, Cheung S, Mok V, Lam L, Leung V, Hui E . Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol Res. 2007; 56(6):509-14. DOI: 10.1016/j.phrs.2007.09.013. View